Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MTTP | P55157 | 2/20 | 0.39 |
| ▸ | APOB | P04114 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7176879 | 0.91 | SMO (0.42) | SMOKDRABL1MAPTMEN1 | |
| SCHEMBL6805454 | 0.89 | SMO (0.60) | SMOMAPTMEN1KMT2ATRPV1 | |
| SCHEMBL6795019 | 0.89 | KDR (0.52) | SMOKDRABL1MAPTMEN1 | |
| SCHEMBL6791040 | 0.87 | PKM (0.49) | SMOKDRABL1MAPTMEN1 | |
| SCHEMBL6800581 | 0.84 | MAPT (0.46) | SMOKDRABL1MAPTMEN1 | |
| SCHEMBL6639807 | 0.82 | SMO (0.49) | SMOKDRMAPTMEN1KMT2A | |
| SCHEMBL6794029 | 0.82 | MAPT (0.49) | SMOKDRABL1MAPTMEN1 | |
| SCHEMBL6787849 | 0.81 | RAB9A (0.53) | SMOMAPTMEN1KMT2ANPC1 | |
| SCHEMBL6802784 | 0.81 | SMO (0.51) | SMOKDRMAPTMEN1KMT2A | |
| SCHEMBL6804592 | 0.80 | SMO (0.64) | SMOKDRABL1TRPV1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885KDR 3180/4885ABL1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.